Pre-clinical study results of BiTE antibody technology presented at AACR 2010

Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that results from studies highlighting pre-clinical advances with its proprietary BiTE antibody technology were presented at the American Association for Cancer Research (AACR) Annual Meeting in Washington, DC.  

The Company and its collaborators reported pre-clinical data characterizing new BiTE antibodies targeting 11 tumor-associated antigens, including CEA, EGFR, IGFR-1, cMet and FAP-alpha.  The data demonstrate that BiTE antibodies can be generated to target a wide range of tumor antigens of highly different function, size and molecular composition, illustrating the wide applicability of the BiTE antibody technology for the treatment of diverse cancer indications.

"Data presented at AACR this year demonstrates the versatility of the BiTE antibody platform," said Patrick Baeuerle, Ph.D., Micromet's Senior Vice President, Chief Scientific Officer. "The breadth and potency of product candidates developed utilizing our next-generation technology give us confidence that BiTE antibodies have the potential to significantly impact the way cancer is treated."

Researchers will present additional preclinical data on programs utilizing the Company's BiTE technology during the course of the meeting.